Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review
Description
Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Agenus Inc (Agenus) is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. The company is advancing therapies targeting cancer through a pipeline of immunological agents. Its portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. The company's products are primarily used by healthcare providers to treat various cancers, including colorectal and melanoma. Agenus is headquartered in Lexington, Massachusetts, the US.
Agenus Inc Key Recent Developments
Mar 17,2026: Agenus to Present Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer at AACR 2026
Mar 16,2026: Agenus Reports 2025 Results as BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally
Mar 16,2026: Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Feb 19,2026: Agenus Biomarker Analysis Shows Survival Stratification in MSS mCRC and Other Cold Tumors With BOT+BAL
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Agenus Inc (Agenus) is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. The company is advancing therapies targeting cancer through a pipeline of immunological agents. Its portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. The company's products are primarily used by healthcare providers to treat various cancers, including colorectal and melanoma. Agenus is headquartered in Lexington, Massachusetts, the US.
Agenus Inc Key Recent Developments
Mar 17,2026: Agenus to Present Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer at AACR 2026
Mar 16,2026: Agenus Reports 2025 Results as BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally
Mar 16,2026: Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Feb 19,2026: Agenus Biomarker Analysis Shows Survival Stratification in MSS mCRC and Other Cold Tumors With BOT+BAL
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
57 Pages
- Section 1 - About the Company
- Agenus Inc - Key Facts
- Agenus Inc - Key Employees
- Agenus Inc - Key Employee Biographies
- Agenus Inc - Major Products and Services
- Agenus Inc - History
- Agenus Inc - Company Statement
- Agenus Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Agenus Inc - Business Description
- Geographical Segment: Rest Of World
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- Agenus Inc - Corporate Strategy
- Agenus Inc - SWOT Analysis
- SWOT Analysis - Overview
- Agenus Inc - Strengths
- Agenus Inc - Weaknesses
- Agenus Inc - Opportunities
- Agenus Inc - Threats
- Agenus Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Agenus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Agenus Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Mar 17, 2026: Agenus to Present Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer at AACR 2026
- Mar 16, 2026: Agenus Reports 2025 Results as BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally
- Mar 16, 2026: Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- Feb 19, 2026: Agenus Biomarker Analysis Shows Survival Stratification in MSS mCRC and Other Cold Tumors With BOT+BAL
- Feb 09, 2026: Agenus to Present Data at AACR-IO on Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
- Jan 16, 2026: Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal
- Jan 15, 2026: Agenus Closes $141M Collaboration With Zydus Lifesciences to Advance BOT+BAL and Secure U.S. Manufacturing Capacity
- Nov 18, 2025: Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer
- Nov 10, 2025: Agenus Reports Third Quarter 2025 Results Highlighting Clinical and Regulatory Advances
- Oct 17, 2025: Agenus Reports 39% Two-Year Survival Rate with BOT/BAL in Multiple Refractory Solid Tumors
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Agenus Inc, Key Facts
- Agenus Inc, Key Employees
- Agenus Inc, Key Employee Biographies
- Agenus Inc, Major Products and Services
- Agenus Inc, History
- Agenus Inc, Subsidiaries
- Agenus Inc, Key Competitors
- Agenus Inc, Ratios based on current share price
- Agenus Inc, Annual Ratios
- Agenus Inc, Annual Ratios (Cont...1)
- Agenus Inc, Annual Ratios (Cont...2)
- Agenus Inc, Interim Ratios
- Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Agenus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
- Agenus Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Agenus Inc, Performance Chart (2021 - 2025)
- Agenus Inc, Ratio Charts
- Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
- Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
